– CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum’s disease treatment. NEW TAIPEI CITY, March 3, 2024 /PRNewswire/ — Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted…
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum’s Disease
This post was originally published on this site